Drug Trial Radar · NCT05289492
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
May 1, 2022
Primary completion
Nov 29, 2023
Study completion Nov 29, 2023
Sponsor
- Lead sponsor
- iTeos TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb; GlaxoSmithKline; iTeos Belgium SA
- First posted
- Mar 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
EOS884448Drug
EOS884448 will be administered in arm A,B and C
IberdomideDrug
Iberdomide will be administered in arm B and C
DexamethasoneDrug
Dexamethasone will be administered in arm C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with any adverse events (AEs) and serious adverse events (SAEs)Time frame: From first study treatment administration up to 120 days after the last dose
- Number of participants with dose limiting toxicity (DLT)Time frame: From first study treatment administration up to 120 days after the last dose
- Recommended Phase 2 dose (RP2D) of EOS884448 alone or in combinations with iberdomide with or without dexamethasone in participants with relapse/refractory multiple myelomaTime frame: up to 2 years
- Number of participants with overall response (partial or better) as determined by IMWG criteriaTime frame: up to 2 years
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona
Eastern Connecticut Hematology & Oncology
Norwich, Connecticut
Hackensack University Medical Center
Hackensack, New Jersey
Fred Hutchinson Cancer Center
Seattle, Washington
ZNA Cadix
Antwerp, Belgium
Institut Jules Bordet
Brussels, Belgium
Universitaire Ziekenhuizen KU Leuven
Leuven, Belgium
CHU Amiens
Amiens, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
APHP Hôpital Saint-Antoine
Paris, France
CHU de Poitiers
Poitiers, France
CHU Toulouse
Toulouse, France
Hospital Fundacion Jimenez Diaz
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.